Effect of biologic agents on radiographic progression of rheumatoid arthritis

References

• Guillemin F, Saraux A, Guggenbuhl P, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis. 2005;64(10):1427–1430.
   Google Scholar
• Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659–672.
   PubMed Web of Science ®Google Scholar
• Haraoui B. Assessment and management of rheumatoid arthritis. JRheumatol Suppl. 2009;82:2–10.
   PubMedGoogle Scholar
• Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19 years study of radiographic progression. Arthritis Rheum. 1998;41(9):1571–1582.
   PubMedGoogle Scholar
• Hulsmans HM, Jacobs JW, van der Heijde DM, et al. The course of radiologic damage during the six years of rheumatoid arthritis. Arthritis Rheum. 2000;43(9):1927–1940.
   Google Scholar
• Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11 Suppl 1:S1.
   Google Scholar
• Devauchelle-Pensec V, Josseaume T, Samjee I, Dougados M, Combe B, Saraux A. Ability of oblique foot radiographs to detect erosions in early arthritis: results in the ESPOIR cohort. Arthritis Rheum. 2008;59(12):1729–1734.
   Google Scholar
• Baron G, Boutron I, Giraudeau B, Ravaud P. Reporting of radiographic methods in randomized controlled trials assessing structural outcomes in rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):651–657.
   Web of Science ®Google Scholar
• Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis. 2001;60(9):817–827.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM. How to read radiographs according to the Sharp/ van der Heijde Method. JRheumatol. 2000;27:261–263.
   PubMed Web of Science ®Google Scholar
• Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum. 1971;14(6):706–720.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995;34 Suppl 2:74–78.
   Google Scholar
• Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum. 1998;41(9):1583–1590.
   PubMed Web of Science ®Google Scholar
• Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, et al. Longterm outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum. 2002;47(4):383–390.
   Google Scholar
• van der Heijde DM, Boonen A, Boers M, et al. Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology (Oxford). 1999;38(12):1213–1220.
   Web of Science ®Google Scholar
• Devauchelle-Pensec V, Berthelot JM, Jousse S, et al. Performance of hand radiographs in predicting the diagnosis in patients with early arthritis. J Rheumatol. 2006 33(8):1511–1515.
   Web of Science ®Google Scholar
• Guillemin F, Billot L, Boini S, Gerard N, 0degaard S, Kvien TK. Reproducibility and sensitivity to change of 5 methods for scoring hand radiographic damage in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):778–786.
   Web of Science ®Google Scholar
• Combe B, Benessiano J, Berenbaum F, et al. The ESPOIR cohort: A ten-year follow-up of early arthritis in France: Methodology and baseline characteristics of the 813 included patients. Joint Bone Spine. 2007;74(5):440–445.
   Web of Science ®Google Scholar
• Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):578–582.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate alone and combined in the treatment of rheumatoid arthritis: two year clinical and radiographic results from the TEMPO study, a double blind, randomized trial. Arthritis Rheum. 2006;54(4):1063–1074.
   PubMed Web of Science ®Google Scholar
• Lukas C, van der Heijde D, Fatenejad S, Landewe R. Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann Rheum Dis. 2010;69(5):851–855.
   Web of Science ®Google Scholar
• Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67(10):1360–1364.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861–1874.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363(9410):675–681.
   PubMed Web of Science ®Google Scholar
• Smolen JS, van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702–710.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52(4):1020–1030.
   PubMedGoogle Scholar
• Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443–1450.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewe R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis. 2008;67(9):1267–1270.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–2806.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocili- zumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–2829.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–1167.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865–876.
   PubMed Web of Science ®Google Scholar
• Smolen JS, van der Heijde DM, Aletaha D, et al. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis. 2009;68(10):1535–1540.
   Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etan- ercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–1593.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32(7):1232–1242.
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, et al. Effect of the treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled study. Lancet. 2004;364(9430):263–269.
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology. 2009;48(9):1114–1121.
   PubMed Web of Science ®Google Scholar